Quintrio
Home

PHARMACEUTICAL PREPARATIONS

PepGen Inc. Common Stock

PEPG

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.

Last trade $3.84
Day change -$0.35 (-8.35%)
Day range $3.62 – $4.21
Volume 4,015,381
Market cap $290M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$290.2M
Price / earnings
—
Price / book
2.82×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.49×

Profitability

Earnings per share
-$1.06
Return on assets
-57.37%
Return on equity
-71.13%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
8.7×
Quick ratio
8.7×
Cash ratio
1.78×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$63.28M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PEPG, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$5.91M$6.42M$5.94M$5.85M$5.23M$5.54M$5.94M$5.38M
Research and development$14.48M$12.52M$13M$13.85M$13.42M$18.39M$25.38M$18.96M
Total operating expenses$20.38M$18.94M$18.94M$19.71M$18.65M$23.93M$31.32M$24.35M
Operating income-$20.38M-$18.94M-$18.94M-$19.71M-$18.65M-$23.93M-$31.32M-$24.35M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$19.38M-$17.8M-$17.75M-$18.29M-$18.03M-$23.09M-$30.2M-$22.86M
Income taxes$13K$16K$15K$49K$0$0$0-$617K
Net income-$19.39M-$17.81M-$17.76M-$18.34M-$18.03M-$23.09M-$30.2M-$22.24M
Net income attributable to common shareholders-$19.39M-$17.81M-$17.76M-$18.34M-$18.03M-$23.09M-$30.2M-$22.24M
EBITDA-$20.14M-$18.69M-$18.62M-$19.37M-$18.32M-$23.6M-$30.93M-$23.97M
Basic earnings per share-$0.28-$0.26-$0.26-$0.27-$0.52-$0.70-$0.92-$0.68
Diluted earnings per share-$0.28-$0.26-$0.26-$0.27-$0.52-$0.70-$0.92-$0.68

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Outlook

The global Peptide Drug Conjugate (PDC) market is projected to reach $1.5 billion by 2031, growing at over 14% CAGR from 2021-2025. PDCs offer targeted drug delivery solutions for oncology and other diseases with reduced systemic toxicity. The market features over 50 clinical candidates and 18 proprietary technologies, with major players including Novartis, Oncopeptides, Bicycle Therapeutics, Cybrexa Therapeutics, and PepGen driving innovation through strategic partnerships and technological advancements in peptide design and linker technologies.

Benzinga

S&P 500 Falls 1%; Accenture Posts Upbeat Earnings

U.S. stocks traded lower midday, with the S&P 500 dropping 1%. Accenture reported strong Q4 earnings, beating analyst estimates, while several other companies experienced significant stock price movements.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.